^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

tolinapant (ASTX660)

i
Company:
Otsuka
Drug class:
XIAP antagonist, cIAP1 antagonist, cIAP2 antagonist
Phase 1
National Cancer Institute (NCI)
Suspended
Last update posted :
02/06/2025
Initiation :
08/04/2025
Primary completion :
05/17/2027
Completion :
05/17/2027
RIPK1
|
Halaven (eribulin mesylate) • tolinapant (ASTX660)